Home › Funds › ORBIMED ADVISORS LLC › PTGX
ORBIMED ADVISORS LLC position in PTGX
PROTAGONIST THERAPEUTICS INC · Health Care
ORBIMED ADVISORS LLC reported holding 150,000 shares of PTGX (PROTAGONIST THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$21.1M, representing 0.43% of its reported portfolio and ranking #48 among its reported holdings. ORBIMED ADVISORS LLC has disclosed PTGX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How ORBIMED ADVISORS LLC's PTGX position evolved
ORBIMED ADVISORS LLC first disclosed a stake in PTGX in Q4 2025 at 21,700 shares (US$1.9M). The position peaked in Q3 2026 at 150,000 shares, worth US$21.1M. Across 4 filings, ORBIMED ADVISORS LLC increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 150,000 shares valued at US$21.1M — an increase of 107,900 shares quarter over quarter.. Notable position changes include a 94% increase in Q1 2026 (shares rose 16% over the following quarter), a 256% increase in Q3 2026 (shares fell 11% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 21.70K | $1.90M | New |
| Q1 2026 | 42.10K | $4.44M | Add |
| Q2 2026 | 42.10K | $5.16M | Hold |
| Q3 2026 | 150.00K | $21.13M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PTGX and 13F data
PTGX (PROTAGONIST THERAPEUTICS INC) is a Health Care company. 49 other funds we track also report a position in PTGX — the largest reported positions include FARALLON CAPITAL MANAGEMENT, L.L.C. (US$907.0M), Farallon Capital Management (US$778.2M), RTW INVESTMENTS, LP (US$713.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PTGX
- FARALLON CAPITAL MANAGEMENT, L.L.C. 6.44M sh · $907.04M · Q3 2026
- Farallon Capital Management 6.35M sh · $778.25M · Q2 2026
- RTW INVESTMENTS, LP 5.06M sh · $713.07M · Q3 2026
- JOHNSON & JOHNSON 2.45M sh · $345.07M · Q3 2026
- Woodline Partners LP 1.41M sh · $198.59M · Q3 2026
- ADAR1 Capital Management, LLC 951.40K sh · $134.04M · Q3 2026
- Hood River Capital Management LLC 893.48K sh · $125.88M · Q3 2026
- PERCEPTIVE ADVISORS LLC 836.58K sh · $117.87M · Q3 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 676.82K sh · $95.36M · Q3 2026
- 683 Capital Management, LLC 255.00K sh · $35.93M · Q3 2026
- Eagle Health Investments LP 248.32K sh · $34.99M · Q3 2026
More on ORBIMED ADVISORS LLC
FAQ
How long has ORBIMED ADVISORS LLC held PTGX?
ORBIMED ADVISORS LLC has disclosed PTGX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is ORBIMED ADVISORS LLC's current position in PTGX?
As of Q3 2026, ORBIMED ADVISORS LLC holds 150.00K shares of PTGX (PROTAGONIST THERAPEUTICS INC), valued at $21.13M, representing 0.43% of its reported portfolio and ranking #48.
Has ORBIMED ADVISORS LLC been buying or selling PTGX?
In the latest 13F filing (Q3 2026), ORBIMED ADVISORS LLC increased its position in PTGX. The position peaked in Q3 2026 at 150.00K shares.
Which other funds hold PTGX?
Other major institutional holders of PTGX include FARALLON CAPITAL MANAGEMENT, L.L.C., Farallon Capital Management, RTW INVESTMENTS, LP, among 49 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.